Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients

被引:61
作者
Maltoni, M
Fabbri, L
Nanni, O
Scarpi, E
Pezzi, L
Flamini, E
Riccobon, A
Derni, S
Pallotti, G
Amadori, D
机构
[1] IST ONCOL ROMAGNOLO,UNITA OPERAT BIOSTAT,FORLI,ITALY
[2] OSPED PIERANTONI,LAB ANAL & RIC CLIN,I-47100 FORLI,ITALY
关键词
cancer; anorexia; cachexia; tumour necrosis factor; interleukin; interferon;
D O I
10.1007/BF01262570
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer anorexia-cachexia syndrome (CACS), which is characterized by progressive weight loss (WL) and anorexia (A), is present in 50% of advanced cancer patients and in 80% of terminally ill cancer patients. One of the most controversial aspects of CACS is its oetiopathogenesis; experimental studies have identified certain cytokines [Tumour necrosis factor alpha (TNF-alpha), interleukin 1 (IL-1), interleukin 6 (IL-6), and gamma interferon (gamma-IFN)] as possible cofactors in the onset of the syndrome. The aim of our study was to investigate the correlation between serum levels of circulating cytokines and severity of CACS. The following series of parameters was indentified in 61 patients with advanced and terminal cancer: stage of disease; Karnofsky performance status (KPS) and clinical symptoms; biohumoral, anthropometric and immunological situation; level of circulating cytokines. All these parameters were evaluated for a possible link with WL/A. Our data do not show any significant correlation between circulating cytokines and WL/A. A direct correlation was identified between WL/A and nausea (P=0.03 and P<0.001, respectively) whereas inverse correlations were observed for both factors as regards arm circumference (P<0.001 for both), wrist circumference (P<0.001 for both), KPS (P<0.001 and P=0.003, respectively) and creatinine (P=0.005 and P=0.03, respectively). Other biochemical factors, such as haemoglobin, haematocrit, glycaemia, prealbumin, sodium and chlorine were also correlated with at least one of the two clinical parameters in question. Unexpected results were seen in the increases in CD20 and CD4 and in the CD4/CD8 ratio. Serum levels of these cytokines do not, therefore, appear to be critical in the onset of CACS. On the contrary, our findings confirmed the clinico-laboratory picture that is characteristic of CACS. If we consider the possibility that CACS is provoked by an aspecific response of the host's defence mechanisms against prolonged neoplastic attack, the increase in CD4 (helper lymphocytes) could be linked to the persistent response.
引用
收藏
页码:130 / 135
页数:6
相关论文
共 33 条
[11]   TUMOR-NECROSIS-FACTOR AND CACHEXIA - A CURRENT PERSPECTIVE [J].
ESPAT, NJ ;
COPELAND, EM ;
MOLDAWER, LL .
SURGICAL ONCOLOGY-OXFORD, 1994, 3 (05) :255-262
[12]   PURIFICATION AND CHARACTERIZATION OF AN INHIBITOR (SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR) FOR TUMOR-NECROSIS-FACTOR AND LYMPHOTOXIN OBTAINED FROM THE SERUM ULTRAFILTRATES OF HUMAN CANCER-PATIENTS [J].
GATANAGA, T ;
HWANG, CD ;
KOHR, W ;
CAPPUCCINI, F ;
LUCCI, JA ;
JEFFES, EWB ;
LENTZ, R ;
TOMICH, J ;
YAMAMOTO, RS ;
GRANGER, GA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) :8781-8784
[13]  
GEMLO BT, 1988, CANCER RES, V48, P5864
[14]  
Havell E A, 1992, Immunol Ser, V56, P341
[15]   CANCER CACHEXIA [J].
KERN, KA ;
NORTON, JA .
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 1988, 12 (03) :286-298
[16]  
LANGSTEIN HN, 1989, SURG FORUM, V15, P408
[17]  
MALTONI M, 1995, CANCER-AM CANCER SOC, V75, P2613, DOI 10.1002/1097-0142(19950515)75:10<2613::AID-CNCR2820751032>3.0.CO
[18]  
2-1
[19]   MONOCYTIC PRODUCTION AND PLASMA BIOACTIVITIES OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR IN HUMAN CANCER [J].
MOLDAWER, LL ;
DROTT, C ;
LUNDHOLM, K .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1988, 18 (05) :486-492
[20]   PURIFICATION OF A LIPOPROTEIN LIPASE-INHIBITING PROTEIN PRODUCED BY A MELANOMA CELL-LINE ASSOCIATED WITH CANCER CACHEXIA [J].
MORI, M ;
YAMAGUCHI, K ;
ABE, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 160 (03) :1085-1092